Pivotal research continues to link metabolic and immune pathways in malignant and neurodegenerative diseases. UCLA scientists identified IGF2BP3 as a key regulator that reprograms metabolism and RNA methylation to fuel leukemia cell survival. Novartis reported preclinical efficacy of VHB-937, a TREM2 agonist monoclonal antibody promoting microglial neuroprotection in CNS diseases including multiple sclerosis. Such studies underscore the complex interplay between cellular metabolism, immune modulation, and disease progression, opening avenues for novel therapeutic strategies employing metabolic and immune targets.